Printer Friendly

GENSIA RECEIVES PATENT ON GENESA SYSTEM TECHNOLOGY

 GENSIA RECEIVES PATENT ON GENESA SYSTEM TECHNOLOGY
 SAN DIEGO, April 30 /PRNewswire/ -- Gensia Pharmaceuticals Inc.


(NASDAQ: GNSA) today announced that a U.S. patent has issued on the company's GenESA System (previously called ESA System) technology. The inventions claimed in the patent include the use of closed-loop administration of catecholamine compounds for the diagnosis and evaluation of coronary artery disease, according to David F. Hale, chairman, president and chief executive officer.
 "The issuance of this patent is an important step in protecting our proprietary position in the GenESA System," said Hale. "We have additional patent applications pending which are directed to specific compounds and other aspects of this technology."
 The GenESA System combines a drug, arbutamine and a computer- controlled drug delivery system designed to pharmacologically stress the heart to aid in the diagnosis of coronary artery disease. It is designed for use with widely used methods of cardiac diagnostic testing including electrocardiography (ECG), echocardiography and radionuclide imaging.
 Phase 3 clinical trials with arbutamine and the GenESA System have been initiated in the United States and the United Kingdom. The Phase 3 clinical program is expected to expand to approximately 60 medical centers in the United States, Western Europe and Canada. The company plans to complete Phase 3 clinical trials with the GenESA System at the end of 1992 with regulatory submissions planned in the United States, Western Europe and Canada in mid-1993.
 A primary clinical need for the GenESA System is for use with patients who are unable to undergo physical exercise stress tests or who have had inconclusive exercise stress ECG tests.
 The company estimates that in the United States, as many as 1.5 million patients who are candidates for testing for coronary artery disease are unable to exercise adequately because of physical disabilities or limitations. In addition, of the 6 million exercise stress ECGs performed each year in the United States, an estimated 20 percent to 30 percent of tests are inconclusive, frequently because the patient is unable to achieve a sufficient increase in heart rate for diagnosis of coronary artery disease to be made.
 The GenESA System is also expected to enhance echocardiography and radionuclide imaging procedures which are difficult to perform in conjunction with physical exercise. There are approximately 6 million echocardiography and 1.5 million radionuclide imaging procedures performed each year in the United States.
 Gensia Clinical Partners owns certain rights to the GenESA System technology which are subject to a purchase option by Gensia.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel drugs for the treatment and diagnosis of human diseases.
 -0- 4/30/92
 /CONTACT: David F. Hale, chairman, president and CEO, or Martha L. Hough, of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA) CO: Gensia Pharmaceuticals Inc. ST: California IN: MTC SU:


DM-JL -- SD003 -- 4923 04/30/92 12:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:476
Previous Article:NEVADA POWER ANNOUNCES AUCTION PREFERRED EXTENDED
Next Article:GENEVA STEEL ANNOUNCES QUARTERLY RESULTS


Related Articles
GENSIA INITIATES PHASE 3 CLINICAL TRIALS WITH THE GENESA(TM) SYSTEM
GENSIA ANNOUNCES GenESA(R) SYSTEM SCHEDULED FOR CPMP REVIEW IN EUROPE IN DECEMBER
GENSIA ANNOUNCES CPMP RECOMMENDATION FOR APPROVAL OF GenESA(R) SYSTEM IN EUROPE
GENSIA RECEIVES PATENT ON GenESA(R) SYSTEM DRUG
GENSIA NOTIFIED BY FDA OF DEFICIENCIES IN GENSA(R) SYSTEM NDA
GENSIA ANNOUNCES APPROVAL OF GenESA(R) SYSTEM IN DENMARK
GENSIA SUBMITS NDA AMENDMENT FOR GenESA(R) SYSTEM IN U.S.
THREE ARBUTAMINE PHASE 3 MANUSCRIPTS PUBLISHED IN NOVEMBER ISSUE OF THE JOURNAL OF AMERICAN COLLEGE OF CARDIOLOGY
ased 9:00est 03/25:
Gensia Plans to File NDA Amendment for GenESA(R) System in October

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters